報價延遲最少15分鐘:2026/11/14 14:46 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.72 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.76/1.09
|
|
企業價值
6.10B
|
| 資產負債 |
|
每股賬面淨值
5.11
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
1.24B
|
|
每股收益
2.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. |
